Global Zolmitriptan Market

Zolmitriptan Comprehensive Study by Type (Nasal Spray, Orally Disintegrating Tablets, Tablets, Others), Patient Age (Children (below 12 years), Adult), Dosage (2.5 mg, 5 mg), Distribution (Hospital Pharmacy, Retail Pharmacy) Players and Region - Global Market Outlook to 2027

Zolmitriptan Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Zolmitriptan?
Zolmitriptan is the 5HT1-receptor agonist drug prescribed to treat migraine. The Zolmitriptan binds the specifically to the serotonin (5-HT) 1B receptors that results in narrowing the blood vessels connecting brain and thereby inhibiting the pain signals from the brains. These result in blocking the release of the pro-inflammatory neuropeptide that cause headache, nausea and related symptoms. This drug limits the pain caused due to acute migraine attacks however, it is not efficient to prevent the migraine attack. Commercially, it is available in tablet form, orally disintegrating tablet and a nasal spray to improve the migraine symptoms.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledAstraZeneca (United Kingdom), Glenmark (India), Amneal Pharmaceuticals, Inc. (United States), Zydus Cadila (India), Zosano Pharma Corporation (United States), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (United States), Aurobindo Pharma Limited (India), Sun Pharmaceutical Industries Limited (India) and INKE (Spain)


The study covers a detailed analysis segmented by key business segments i.e. by type (Nasal Spray, Orally Disintegrating Tablets, Tablets and Others) and major geographies.

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Zolmitriptan market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are AstraZeneca (United Kingdom), Glenmark (India), Amneal Pharmaceuticals, Inc. (United States), Zydus Cadila (India), Zosano Pharma Corporation (United States), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (United States), Aurobindo Pharma Limited (India), Sun Pharmaceutical Industries Limited (India) and INKE (Spain).

Market Overview:
In May 2018, the Amneal Pharmaceuticals LLC acquired 100% stakes of the Impax Laboratories, Inc. Through this strategic move, the company Amneal Pharmaceuticals LLC expanded the product portfolio, enhance extensive R&D and manufacturing infrastructure.
In 2018, Zydus Cadila received US Food and Drug Administration (USFDA) approval for the Zolmitriptan tablet prescribed to relive the migraine symptoms. The approval is issued for the Zolmitriptan tablet in 2.5 mg and 5 mg dosage

Restraints
  • Side Effects of zolmitriptan


Key highlights of the Global Zolmitriptan market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Zolmitriptan market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Zolmitriptan market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Zolmitriptan Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Zolmitriptan market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Zolmitriptan market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Manufacturers of Zolmitriptan, Manufacturers of Migraine Drugs, Contract Research Organization and Research Institutes.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Nasal Spray
  • Orally Disintegrating Tablets
  • Tablets
  • Others
By Patient Age
  • Children (below 12 years)
  • Adult

By Dosage
  • 2.5 mg
  • 5 mg

By Distribution
  • Hospital Pharmacy
  • Retail Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in prevalence of Migraine
    • 3.3. Market Challenges
      • 3.3.1. Alternative treatment or medication for treating migraine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Zolmitriptan, by Type, Patient Age, Dosage, Distribution and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Zolmitriptan (Value)
      • 5.2.1. Global Zolmitriptan by: Type (Value)
        • 5.2.1.1. Nasal Spray
        • 5.2.1.2. Orally Disintegrating Tablets
        • 5.2.1.3. Tablets
        • 5.2.1.4. Others
      • 5.2.2. Global Zolmitriptan by: Patient Age (Value)
        • 5.2.2.1. Children (below 12 years)
        • 5.2.2.2. Adult
      • 5.2.3. Global Zolmitriptan by: Dosage (Value)
        • 5.2.3.1. 2.5 mg
        • 5.2.3.2. 5 mg
      • 5.2.4. Global Zolmitriptan Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Zolmitriptan (Price)
      • 5.3.1. Global Zolmitriptan by: Type (Price)
  • 6. Zolmitriptan: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Glenmark (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amneal Pharmaceuticals, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Zydus Cadila (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Zosano Pharma Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Viatris Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Aurobindo Pharma Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sun Pharmaceutical Industries Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. INKE (Spain)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Zolmitriptan Sale, by Type, Patient Age, Dosage, Distribution and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Zolmitriptan (Value)
      • 7.2.1. Global Zolmitriptan by: Type (Value)
        • 7.2.1.1. Nasal Spray
        • 7.2.1.2. Orally Disintegrating Tablets
        • 7.2.1.3. Tablets
        • 7.2.1.4. Others
      • 7.2.2. Global Zolmitriptan by: Patient Age (Value)
        • 7.2.2.1. Children (below 12 years)
        • 7.2.2.2. Adult
      • 7.2.3. Global Zolmitriptan by: Dosage (Value)
        • 7.2.3.1. 2.5 mg
        • 7.2.3.2. 5 mg
      • 7.2.4. Global Zolmitriptan Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Zolmitriptan (Price)
      • 7.3.1. Global Zolmitriptan by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Zolmitriptan: by Type(USD Million)
  • Table 2. Zolmitriptan Nasal Spray , by Region USD Million (2016-2021)
  • Table 3. Zolmitriptan Orally Disintegrating Tablets , by Region USD Million (2016-2021)
  • Table 4. Zolmitriptan Tablets , by Region USD Million (2016-2021)
  • Table 5. Zolmitriptan Others , by Region USD Million (2016-2021)
  • Table 6. Zolmitriptan: by Patient Age(USD Million)
  • Table 7. Zolmitriptan Children (below 12 years) , by Region USD Million (2016-2021)
  • Table 8. Zolmitriptan Adult , by Region USD Million (2016-2021)
  • Table 9. Zolmitriptan: by Dosage(USD Million)
  • Table 10. Zolmitriptan 2.5 mg , by Region USD Million (2016-2021)
  • Table 11. Zolmitriptan 5 mg , by Region USD Million (2016-2021)
  • Table 12. South America Zolmitriptan, by Country USD Million (2016-2021)
  • Table 13. South America Zolmitriptan, by Type USD Million (2016-2021)
  • Table 14. South America Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 15. South America Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 16. South America Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 17. Brazil Zolmitriptan, by Type USD Million (2016-2021)
  • Table 18. Brazil Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 19. Brazil Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 20. Brazil Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 21. Argentina Zolmitriptan, by Type USD Million (2016-2021)
  • Table 22. Argentina Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 23. Argentina Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 24. Argentina Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 25. Rest of South America Zolmitriptan, by Type USD Million (2016-2021)
  • Table 26. Rest of South America Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 27. Rest of South America Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 28. Rest of South America Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 29. Asia Pacific Zolmitriptan, by Country USD Million (2016-2021)
  • Table 30. Asia Pacific Zolmitriptan, by Type USD Million (2016-2021)
  • Table 31. Asia Pacific Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 32. Asia Pacific Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 33. Asia Pacific Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 34. China Zolmitriptan, by Type USD Million (2016-2021)
  • Table 35. China Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 36. China Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 37. China Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 38. Japan Zolmitriptan, by Type USD Million (2016-2021)
  • Table 39. Japan Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 40. Japan Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 41. Japan Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 42. India Zolmitriptan, by Type USD Million (2016-2021)
  • Table 43. India Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 44. India Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 45. India Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 46. South Korea Zolmitriptan, by Type USD Million (2016-2021)
  • Table 47. South Korea Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 48. South Korea Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 49. South Korea Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 50. Taiwan Zolmitriptan, by Type USD Million (2016-2021)
  • Table 51. Taiwan Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 52. Taiwan Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 53. Taiwan Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 54. Australia Zolmitriptan, by Type USD Million (2016-2021)
  • Table 55. Australia Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 56. Australia Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 57. Australia Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 58. Rest of Asia-Pacific Zolmitriptan, by Type USD Million (2016-2021)
  • Table 59. Rest of Asia-Pacific Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 60. Rest of Asia-Pacific Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 61. Rest of Asia-Pacific Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 62. Europe Zolmitriptan, by Country USD Million (2016-2021)
  • Table 63. Europe Zolmitriptan, by Type USD Million (2016-2021)
  • Table 64. Europe Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 65. Europe Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 66. Europe Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 67. Germany Zolmitriptan, by Type USD Million (2016-2021)
  • Table 68. Germany Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 69. Germany Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 70. Germany Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 71. France Zolmitriptan, by Type USD Million (2016-2021)
  • Table 72. France Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 73. France Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 74. France Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 75. Italy Zolmitriptan, by Type USD Million (2016-2021)
  • Table 76. Italy Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 77. Italy Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 78. Italy Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 79. United Kingdom Zolmitriptan, by Type USD Million (2016-2021)
  • Table 80. United Kingdom Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 81. United Kingdom Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 82. United Kingdom Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 83. Netherlands Zolmitriptan, by Type USD Million (2016-2021)
  • Table 84. Netherlands Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 85. Netherlands Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 86. Netherlands Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 87. Rest of Europe Zolmitriptan, by Type USD Million (2016-2021)
  • Table 88. Rest of Europe Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 89. Rest of Europe Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 90. Rest of Europe Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 91. MEA Zolmitriptan, by Country USD Million (2016-2021)
  • Table 92. MEA Zolmitriptan, by Type USD Million (2016-2021)
  • Table 93. MEA Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 94. MEA Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 95. MEA Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 96. Middle East Zolmitriptan, by Type USD Million (2016-2021)
  • Table 97. Middle East Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 98. Middle East Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 99. Middle East Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 100. Africa Zolmitriptan, by Type USD Million (2016-2021)
  • Table 101. Africa Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 102. Africa Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 103. Africa Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 104. North America Zolmitriptan, by Country USD Million (2016-2021)
  • Table 105. North America Zolmitriptan, by Type USD Million (2016-2021)
  • Table 106. North America Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 107. North America Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 108. North America Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 109. United States Zolmitriptan, by Type USD Million (2016-2021)
  • Table 110. United States Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 111. United States Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 112. United States Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 113. Canada Zolmitriptan, by Type USD Million (2016-2021)
  • Table 114. Canada Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 115. Canada Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 116. Canada Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 117. Mexico Zolmitriptan, by Type USD Million (2016-2021)
  • Table 118. Mexico Zolmitriptan, by Patient Age USD Million (2016-2021)
  • Table 119. Mexico Zolmitriptan, by Dosage USD Million (2016-2021)
  • Table 120. Mexico Zolmitriptan, by Distribution USD Million (2016-2021)
  • Table 121. Zolmitriptan: by Type(USD/Units)
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Zolmitriptan: by Type(USD Million)
  • Table 133. Zolmitriptan Nasal Spray , by Region USD Million (2022-2027)
  • Table 134. Zolmitriptan Orally Disintegrating Tablets , by Region USD Million (2022-2027)
  • Table 135. Zolmitriptan Tablets , by Region USD Million (2022-2027)
  • Table 136. Zolmitriptan Others , by Region USD Million (2022-2027)
  • Table 137. Zolmitriptan: by Patient Age(USD Million)
  • Table 138. Zolmitriptan Children (below 12 years) , by Region USD Million (2022-2027)
  • Table 139. Zolmitriptan Adult , by Region USD Million (2022-2027)
  • Table 140. Zolmitriptan: by Dosage(USD Million)
  • Table 141. Zolmitriptan 2.5 mg , by Region USD Million (2022-2027)
  • Table 142. Zolmitriptan 5 mg , by Region USD Million (2022-2027)
  • Table 143. South America Zolmitriptan, by Country USD Million (2022-2027)
  • Table 144. South America Zolmitriptan, by Type USD Million (2022-2027)
  • Table 145. South America Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 146. South America Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 147. South America Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 148. Brazil Zolmitriptan, by Type USD Million (2022-2027)
  • Table 149. Brazil Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 150. Brazil Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 151. Brazil Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 152. Argentina Zolmitriptan, by Type USD Million (2022-2027)
  • Table 153. Argentina Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 154. Argentina Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 155. Argentina Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 156. Rest of South America Zolmitriptan, by Type USD Million (2022-2027)
  • Table 157. Rest of South America Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 158. Rest of South America Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 159. Rest of South America Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 160. Asia Pacific Zolmitriptan, by Country USD Million (2022-2027)
  • Table 161. Asia Pacific Zolmitriptan, by Type USD Million (2022-2027)
  • Table 162. Asia Pacific Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 163. Asia Pacific Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 164. Asia Pacific Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 165. China Zolmitriptan, by Type USD Million (2022-2027)
  • Table 166. China Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 167. China Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 168. China Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 169. Japan Zolmitriptan, by Type USD Million (2022-2027)
  • Table 170. Japan Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 171. Japan Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 172. Japan Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 173. India Zolmitriptan, by Type USD Million (2022-2027)
  • Table 174. India Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 175. India Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 176. India Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 177. South Korea Zolmitriptan, by Type USD Million (2022-2027)
  • Table 178. South Korea Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 179. South Korea Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 180. South Korea Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 181. Taiwan Zolmitriptan, by Type USD Million (2022-2027)
  • Table 182. Taiwan Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 183. Taiwan Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 184. Taiwan Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 185. Australia Zolmitriptan, by Type USD Million (2022-2027)
  • Table 186. Australia Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 187. Australia Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 188. Australia Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 189. Rest of Asia-Pacific Zolmitriptan, by Type USD Million (2022-2027)
  • Table 190. Rest of Asia-Pacific Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 191. Rest of Asia-Pacific Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 192. Rest of Asia-Pacific Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 193. Europe Zolmitriptan, by Country USD Million (2022-2027)
  • Table 194. Europe Zolmitriptan, by Type USD Million (2022-2027)
  • Table 195. Europe Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 196. Europe Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 197. Europe Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 198. Germany Zolmitriptan, by Type USD Million (2022-2027)
  • Table 199. Germany Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 200. Germany Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 201. Germany Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 202. France Zolmitriptan, by Type USD Million (2022-2027)
  • Table 203. France Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 204. France Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 205. France Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 206. Italy Zolmitriptan, by Type USD Million (2022-2027)
  • Table 207. Italy Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 208. Italy Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 209. Italy Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 210. United Kingdom Zolmitriptan, by Type USD Million (2022-2027)
  • Table 211. United Kingdom Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 212. United Kingdom Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 213. United Kingdom Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 214. Netherlands Zolmitriptan, by Type USD Million (2022-2027)
  • Table 215. Netherlands Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 216. Netherlands Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 217. Netherlands Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 218. Rest of Europe Zolmitriptan, by Type USD Million (2022-2027)
  • Table 219. Rest of Europe Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 220. Rest of Europe Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 221. Rest of Europe Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 222. MEA Zolmitriptan, by Country USD Million (2022-2027)
  • Table 223. MEA Zolmitriptan, by Type USD Million (2022-2027)
  • Table 224. MEA Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 225. MEA Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 226. MEA Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 227. Middle East Zolmitriptan, by Type USD Million (2022-2027)
  • Table 228. Middle East Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 229. Middle East Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 230. Middle East Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 231. Africa Zolmitriptan, by Type USD Million (2022-2027)
  • Table 232. Africa Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 233. Africa Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 234. Africa Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 235. North America Zolmitriptan, by Country USD Million (2022-2027)
  • Table 236. North America Zolmitriptan, by Type USD Million (2022-2027)
  • Table 237. North America Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 238. North America Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 239. North America Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 240. United States Zolmitriptan, by Type USD Million (2022-2027)
  • Table 241. United States Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 242. United States Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 243. United States Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 244. Canada Zolmitriptan, by Type USD Million (2022-2027)
  • Table 245. Canada Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 246. Canada Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 247. Canada Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 248. Mexico Zolmitriptan, by Type USD Million (2022-2027)
  • Table 249. Mexico Zolmitriptan, by Patient Age USD Million (2022-2027)
  • Table 250. Mexico Zolmitriptan, by Dosage USD Million (2022-2027)
  • Table 251. Mexico Zolmitriptan, by Distribution USD Million (2022-2027)
  • Table 252. Zolmitriptan: by Type(USD/Units)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Zolmitriptan: by Type USD Million (2016-2021)
  • Figure 5. Global Zolmitriptan: by Patient Age USD Million (2016-2021)
  • Figure 6. Global Zolmitriptan: by Dosage USD Million (2016-2021)
  • Figure 7. South America Zolmitriptan Share (%), by Country
  • Figure 8. Asia Pacific Zolmitriptan Share (%), by Country
  • Figure 9. Europe Zolmitriptan Share (%), by Country
  • Figure 10. MEA Zolmitriptan Share (%), by Country
  • Figure 11. North America Zolmitriptan Share (%), by Country
  • Figure 12. Global Zolmitriptan: by Type USD/Units (2016-2021)
  • Figure 13. Global Zolmitriptan share by Players 2021 (%)
  • Figure 14. Global Zolmitriptan share by Players (Top 3) 2021(%)
  • Figure 15. Global Zolmitriptan share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 19. Glenmark (India) Revenue, Net Income and Gross profit
  • Figure 20. Glenmark (India) Revenue: by Geography 2021
  • Figure 21. Amneal Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Amneal Pharmaceuticals, Inc. (United States) Revenue: by Geography 2021
  • Figure 23. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 24. Zydus Cadila (India) Revenue: by Geography 2021
  • Figure 25. Zosano Pharma Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Zosano Pharma Corporation (United States) Revenue: by Geography 2021
  • Figure 27. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2021
  • Figure 29. Viatris Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Viatris Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Aurobindo Pharma Limited (India) Revenue, Net Income and Gross profit
  • Figure 32. Aurobindo Pharma Limited (India) Revenue: by Geography 2021
  • Figure 33. Sun Pharmaceutical Industries Limited (India) Revenue, Net Income and Gross profit
  • Figure 34. Sun Pharmaceutical Industries Limited (India) Revenue: by Geography 2021
  • Figure 35. INKE (Spain) Revenue, Net Income and Gross profit
  • Figure 36. INKE (Spain) Revenue: by Geography 2021
  • Figure 37. Global Zolmitriptan: by Type USD Million (2022-2027)
  • Figure 38. Global Zolmitriptan: by Patient Age USD Million (2022-2027)
  • Figure 39. Global Zolmitriptan: by Dosage USD Million (2022-2027)
  • Figure 40. South America Zolmitriptan Share (%), by Country
  • Figure 41. Asia Pacific Zolmitriptan Share (%), by Country
  • Figure 42. Europe Zolmitriptan Share (%), by Country
  • Figure 43. MEA Zolmitriptan Share (%), by Country
  • Figure 44. North America Zolmitriptan Share (%), by Country
  • Figure 45. Global Zolmitriptan: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Glenmark (India)
  • Amneal Pharmaceuticals, Inc. (United States)
  • Zydus Cadila (India)
  • Zosano Pharma Corporation (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Viatris Inc. (United States)
  • Aurobindo Pharma Limited (India)
  • Sun Pharmaceutical Industries Limited (India)
  • INKE (Spain)
Select User Access Type

Key Highlights of Report


May 2022 242 Pages 82 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Zolmitriptan Market Quantitative research analysis
Global Zolmitriptan Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Zolmitriptan Market is heading robustly to achieve new growth cycle.
The Concentration Rate of Global Zolmitriptan market is dominated by Players and may generate healthy valuation by 2027.
Companies that are profiled in Global Zolmitriptan Market are AstraZeneca (United Kingdom), Glenmark (India), Amneal Pharmaceuticals, Inc. (United States), Zydus Cadila (India), Zosano Pharma Corporation (United States), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (United States), Aurobindo Pharma Limited (India), Sun Pharmaceutical Industries Limited (India) and INKE (Spain) etc.

Know More About Global Zolmitriptan Market Report?

Have a Query? Click Here

Other Related Reports

Antiprotozoal drugs Comprehensive Study by Type (Chloroquine, Pyrimethamine, Mefloquine, Hydroxychloroquine, Metronidazole, Atovaquone, Others), Application (Healthcare and Hospital, Others), Form (L...
$ 3350
Pediatrics Respiratory Drugs Comprehensive Study by Disease Type (Asthma, Cystic Fibrosis, Bronchiolitis, Pneumonia, Tuberculosis, Others), Distribution Channel (Hospitals & Clinics, Retail Pharmacie...
$ 3750
Suplatast Tosilate Comprehensive Study by Type (Antiasthmatic agent, Antiallergic agent), Application (Hospitals, Cancer Research Centers, Clinics), Modility (Research, Commercialized), Distribution ...
$ 3350
Postpartum Bleeding Drug Comprehensive Study by Type (Oxytocin, Methergine, Hemabate, Misoprostol, Carboprost, Tranexamic acid, Others), End-user (Hospitals, Maternity Clinics, Out-of-hospital emerge...
$ 3450
Amitriptyline Comprehensive Study by Application (Depression, Migraine, Insomnia, Rheumatic diseases), Form (Tablet, Liquid), Distribution (Online Pharmacy, Hospital Pharmacy, Generic Drug Store), D...
$ 3350
Hemorrhoids Ointment Comprehensive Study by Type (Paste, Gelatinous, Others), Application (Internal Hemorrhoids, External Hemorrhoids, Mixed Hemorrhoids), Distribution Channel (Retail pharmacies, Hos...
$ 3350